Expert Opinion on Emerging Drugs, volume 29, issue 4, pages 361-368

Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis

Heli A. Patel ¹

Linh Tran ^{2, 3}

Ralina Karagenova ^{4, 5}

Steven R. Feldman ^{1, 6, 7, 8, 9, 10}

Hide authors affiliations

Center for Dermatological Research, Wake Forest University, Winston-Salem, NC, USA |

University of Texas Health Science Center at San Antonio, Texas, TX, USA |

University of Texas Health Science Center, San Antonio, TX, USA |

⁴

University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA |

⁵

John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA |

⁶

Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA |

⁷

Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA |

⁸

Department of Dermatology, University of Southern Denmark, Odense, Denmark |

⁹

Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA |

¹⁰

Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA |

Publication type: Journal Article

Publication date: 2024-10-11

Taylor & Francis

Journal: Expert Opinion on Emerging Drugs

scimago Q1

wos Q2

SJR: 0.881

CiteScore: 5.9

Impact factor: 2.7

ISSN: 14728214, 17447623

DOI: 10.1080/14728214.2024.2416114

Copy DOI

Found

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST | RIS | BibTex | MLA

Found error?

Publisher

Taylor & Francis

Journal

Expert Opinion on Emerging Drugs

scimago Q1

wos Q2

SJR

0.881

CiteScore

5.9

Impact factor

2.7

ISSN

14728214 (Print)

17447623 (Electronic)